Inherited BRCA2 mutation associated with high grade breast cancer

被引:73
|
作者
Agnarsson, BA
Jonasson, JG
Björnsdottir, IB
Barkardottir, RB
Egilsson, V
Sigurdsson, H
机构
[1] Univ Iceland, Dept Pathol, IS-121 Reykjavik, Iceland
[2] Univ Hosp Reykjavik, Dept Oncol, Reykjavik, Iceland
关键词
BRCA2; flow cytometry; hereditary breast cancer; malignancy grade; tumor biology;
D O I
10.1023/A:1005853022804
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inheritance is believed to play a major role in 5-10% of breast cancer. The breast cancer susceptibility genes BRCA1 and BRCA2 are estimated to account for more than half of these cases. Recent studies have suggested that breast cancers associated with BRCA1 germline mutations are of higher grade than sporadic cases. The purpose of this investigation was to determine if there are significant pathologic and biologic differences between hereditary BRCA2 related breast carcinomas and non-hereditary breast cancers. Forty cases of hereditary breast cancer from families associated with a specific 999del5 BRCA2 mutation were compared with regard to histologic and biologic factors to an age matched control group. Thirty-four patients (85%) had ductal carcinoma, two had lobular carcinoma, and one patient had medullary carcinoma. Compared to the control group, the BRCA2 tumors had less tubule formation (p = 0.02), more nuclear pleomorphism (p = 0.02), and higher mitotic rates (p = 0.002), and were thus of higher histologic grade (p = 0.003). By flow cytometry the BRCA2 tumors also had significantly higher S-phase fractions than the control tumors (p = 0.02). Significant differences in axillary lymph-node involvement or ploidy status were not detected. According to the results of this study, hereditary breast cancers associated with the 999del5 BRCA2 mutation are high grade tumors with a rapid proliferation rate. Other or additional factors than the defining BRCA2 mutation are involved in determining the tumor type.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 50 条
  • [31] BRCA2 associated breast cancers exhibit a luminal phenotype despite their high histologic grade
    Bane, AL
    Tjan, S
    Weerasooriya, N
    Andrulis, IL
    O'Malley, FP
    LABORATORY INVESTIGATION, 2006, 86 : 21A - 21A
  • [32] BRCA2 gene mutation in cancer
    Xie, Chunbao
    Luo, Jiangrong
    He, Yangjun
    Jiang, Lingxi
    Zhong, Ling
    Shi, Yi
    MEDICINE, 2022, 101 (45) : E31705
  • [33] Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation
    Bonneau, Maeva
    Bellesoeur, Audrey
    BULLETIN DU CANCER, 2023, 110 (11) : 1092 - 1093
  • [34] Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Timothy R Rebbeck
    Susan M Domchek
    Breast Cancer Research, 10
  • [35] BRCA1 and BRCA2 mutation analysis in Irish breast cancer families
    McDevitt, T
    Miller, N
    Ormiston, W
    Cody, N
    Daly, PA
    McDermott, E
    Carney, DE
    Green, AJ
    Barton, DE
    AlKindi, S
    O'Malley, K
    Nolan, C
    JOURNAL OF MEDICAL GENETICS, 2000, 37 : S35 - S35
  • [36] Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    Huzarski, Tomasz
    Aeilts, Amber
    Armel, Susan Randall
    Karlan, Beth
    Singer, Christian
    Eisen, Andrea
    Tung, Nadine
    Olopade, Olufunmilayo
    Bordeleau, Louise
    Eng, Charis
    Foulkes, William
    Neuhausen, Susan
    Cullinane, Carey
    Pal, Tuya
    Fruscio, Robert
    Lubinski, Jan
    Metcalfe, Kelly
    Sun, Ping
    Narod, Steven
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 257 - 264
  • [37] Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
    Joanne Kotsopoulos
    Jacek Gronwald
    Tomasz Huzarski
    Amber Aeilts
    Susan Randall Armel
    Beth Karlan
    Christian F. Singer
    Andrea Eisen
    Nadine Tung
    Olufunmilayo Olopade
    Louise Bordeleau
    Charis Eng
    William D. Foulkes
    Susan L. Neuhausen
    Carey A. Cullinane
    Tuya Pal
    Robert Fruscio
    Jan Lubinski
    Kelly Metcalfe
    Ping Sun
    Steven A. Narod
    Breast Cancer Research and Treatment, 2023, 201 : 257 - 264
  • [38] Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Kelly Metcalfe
    Henry T. Lynch
    Parviz Ghadirian
    Nadine Tung
    Charmaine Kim-Sing
    Olufunmilayo I. Olopade
    Susan Domchek
    Andrea Eisen
    William D. Foulkes
    Barry Rosen
    Danny Vesprini
    Ping Sun
    Steven A. Narod
    Breast Cancer Research and Treatment, 2011, 127 : 287 - 296
  • [39] BRCA1 and BRCA2 mutation screening in sporadic and familial breast cancer
    Ellis, D
    McCall, SH
    Greenman, J
    Evans, G
    Abbs, S
    Hodgson, SV
    Mathew, CG
    JOURNAL OF MEDICAL GENETICS, 1999, 36 : S38 - S38
  • [40] Aspirin and breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Kornhauser, Naomi
    Terry, Mary Beth
    Vahdat, Linda T.
    Andrulis, Irene
    Buys, Saundra
    Daly, Mary
    John, Esther
    Hopper, John L.
    Cigler, Tessa
    CANCER RESEARCH, 2015, 75